PetMed Express, Inc. (NASDAQ:PETS) is a company that specializes in pet medications and health products. It operates primarily through its online platform, providing a convenient way for pet owners to access a wide range of products. The company faces competition from other online pet product retailers and traditional brick-and-mortar stores.
On August 12, 2025, PETS reported an earnings per share (EPS) of -$0.49, which was significantly below the expected EPS of -$0.06. Despite this, the company managed to meet its revenue estimate, reporting $51.1 million. This performance comes amid ongoing scrutiny, as Pomerantz LLP investigates potential securities fraud or other unlawful practices by the company and its executives.
The investigation by Pomerantz LLP follows PetMed's announcement on June 10, 2025, about delaying its fourth quarter and fiscal year 2025 earnings release. This delay, attributed to the need for more time to complete the year-end audit, led to an 11.22% drop in PetMed's stock price, closing at $3.72 per share on June 11, 2025. Further delays in filing the Annual Report were announced on July 1, 2025, adding to investor concerns.
PetMed Express has a price-to-sales ratio of 0.25 suggests that the market values the company at 25 cents for every dollar of sales. Despite these figures, the enterprise value to sales ratio is 0.06, reflecting a relatively low valuation compared to its sales.
The company's financial health is supported by a low debt-to-equity ratio of 0.01, indicating minimal leverage and a strong equity position. With a current ratio of 1.43, PetMed Express has sufficient liquidity to cover its short-term liabilities. The enterprise value to operating cash flow ratio of 2.81 suggests a reasonable valuation in terms of cash flow generation.
